| Description | This product a fully human antibody derived from patients with autoimmune diseases using Epstein-Barr virus technology. EV1007 has a neutralizing effect on GM-CSF activity. CSF2 (granulocyte macrophage colony-stimulating factor) stimulates the survival, proliferation, and differentiation of hematopoietic bone marrow cells. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; Neut |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CSF2 |
| Alternative Name | CSF; GMCSF; granulocyte-macrophage colony-stimulating factor; colony stimulating factor 2 (granulocyte-macrophage); granulocyte macrophage-colony stimulating factor; molgramostim; molgramostin; GM-CSF; Granulocyte-macrophage colony-stimulating factor |
| Gene ID | 1437 |
| UniProt | P04141 |
| Research Area | Immunology |
